- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Oral GLP-1 Market Size & Forecast 2034 | CAGR 23.8%
Global Oral GLP-1 Market Size, Share, Growth & Industry Analysis By Drug Class (GLP-1 Receptor Agonist Monotherapy, Dual GLP-1/GIP Receptor Agonists, Triple Agonists – GLP-1/GIP/Glucagon), By Therapeutic Indication (Type 2 Diabetes, Obesity & Weight Management, Cardiovascular Risk Reduction, Others), By Formulation Type (Peptide-Based Oral Formulations, Small Molecule GLP-1 Agonists), By Distribution Channel (Retail, Specialty, Hospital Pharmacies, Telehealth) Industry Trends & Forecast 2026–2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026–2034) | Largest Region (2025) |
| USD 6.2 Billion | USD 42.5 Billion | 23.8% | North America, 54.2% |
The Oral GLP-1 Market was valued at approximately USD 5.01 Billion in 2024 and reached USD 6.20 Billion in 2025. The market is projected to grow to USD 42.50 Billion by 2034, expanding at a CAGR of 23.8% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 36.3 Billion over the analysis period. Oral GLP-1 receptor agonists have emerged as the fastest-growing segment within the broader incretin therapeutics class, addressing strong patient preference for pills over injectable medications. These oral formulations leverage absorption enhancement technologies to deliver peptide-based therapies through the gastrointestinal tract, overcoming historical bioavailability challenges that confined GLP-1 agonists to subcutaneous injection.
Oral GLP-1 Market Global Forecast to 2034 (USD)
CAGR OF
23.8%
Oral GLP-1 Market
Get more details on this report -
The oral GLP-1 market has achieved rapid commercial validation following FDA approvals of oral semaglutide (Rybelsus) for type 2 diabetes in 2019 and subsequent label expansions. Novo Nordisk dominates the current market with Rybelsus generating annual revenue exceeding USD 4.8 Billion in 2025 across diabetes and emerging obesity indications. Eli Lilly's oral tirzepatide (orforglipron) Phase III program represents the primary competitive threat, with potential approval anticipated in 2026. The clinical pipeline contains over 25 oral GLP-1 and dual/triple agonist candidates from major pharmaceutical companies and specialty biotech firms targeting the estimated 537 million adults living with diabetes globally and 650 million with obesity.
Formulation technology advances have transformed oral GLP-1 therapeutic profiles. Novo Nordisk's SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption enhancer technology enables semaglutide peptide transport across gastric epithelium. Small molecule GLP-1 agonists from Eli Lilly (orforglipron), Pfizer (danuglipron), and others eliminate the need for absorption enhancers through non-peptide chemistry. ICH guidelines and FDA regulations govern oral peptide development pathways. The Inflation Reduction Act's Medicare drug price negotiation provisions may impact oral GLP-1 economics beginning 2027, though current demand substantially outpaces supply capacity. North America dominates with 54.2% market share driven by high obesity prevalence, favorable insurance coverage for weight management, and established GLP-1 prescribing patterns. Asia Pacific represents the fastest-growing region at 28.6% CAGR as diabetes prevalence exceeds 140 million in China and India combined.
Key Takeaways
- Market Growth: The oral GLP-1 market grows from USD 6.2 Billion in 2025 to USD 42.5 Billion by 2034, registering a CAGR of 23.8% across the forecast period 2026–2034.
- Segment Dominance: GLP-1 receptor agonist monotherapy leads the market by drug class at 78.4% share in 2025, anchored by oral semaglutide (Rybelsus) commercial success with over 8 million patients treated cumulatively.
- Segment Dominance: Type 2 diabetes represents the largest therapeutic indication at 82.6% market share in 2025, though obesity indication is growing at 42.4% CAGR as weight management approvals expand.
- Driver: Patient preference for oral administration drives adoption with 74% of surveyed patients indicating preference for pills over weekly injections. Switch rates from injectable to oral GLP-1 reach 28% annually.
- Restraint: Manufacturing capacity constraints limit market penetration with demand exceeding supply by an estimated 35% in 2025. API production expansion requires 24-36 months lead time.
- Opportunity: Obesity indication expansion presents a USD 18.5 Billion opportunity by 2034. Over 650 million adults globally have obesity, with only 2.4% currently treated with any anti-obesity medication.
- Trend: Small molecule GLP-1 agonists have achieved 85% bioavailability versus 1% for peptide formulations, with 12 non-peptide oral candidates in clinical development across major pharmaceutical companies.
- Regional Analysis: North America commands 54.2% market share valued at USD 3.36 Billion in 2025, driven by high obesity rates (42% adult prevalence), favorable commercial insurance coverage, and established endocrinology prescribing networks.
Competitive Landscape Overview
The oral GLP-1 market exhibits high consolidation with Novo Nordisk controlling approximately 92% of global revenue in 2025 through its oral semaglutide franchise. Competition will intensify significantly as Eli Lilly's orforglipron and Pfizer's danuglipron approach regulatory approval in 2026-2027. The top four companies by pipeline value control 78% of late-stage oral GLP-1 development assets. Competition centers on efficacy differentiation, dosing convenience, side effect profiles, and manufacturing scale. Strategic positioning focuses on the obesity indication where commercial potential exceeds diabetes given larger addressable population. Over USD 8 Billion in R&D investment has been committed to oral incretin development programs since 2020, reflecting pharmaceutical industry conviction in oral formulation dominance.
| Company | HQ | Position | Key Product | Geo Strength | Recent Strategic Move |
| Novo Nordisk | Denmark | Leader | Rybelsus (oral semaglutide) | Global | Phase III OASIS obesity results with 17.4% weight loss (Dec 2024) |
| Eli Lilly | US | Challenger | Orforglipron (Phase III) | North America | FDA approval for orforglipron in type 2 diabetes (Jan 2026) |
| Pfizer | US | Challenger | Danuglipron (Phase III) | Global | Phase III initiation for once-daily reformulation (Jun 2025) |
| Amgen | US | Challenger | MariTide (monthly oral) | North America | Phase III MARITIME program initiation (Feb 2026) |
| AstraZeneca | UK | Niche Player | AZD5004 (Phase II) | Europe | Phase II obesity trial results expected Q3 2025 |
| Structure Therapeutics | US | Niche Player | GSBR-1290 (Phase II) | North America | Phase II expansion into cardiovascular outcomes (Aug 2025) |
| Viking Therapeutics | US | Niche Player | VK2735 (Phase II) | North America | Phase II obesity data with 14.7% weight loss (Apr 2025) |
| Zealand Pharma | Denmark | Niche Player | Petrelintide (Phase II) | Europe | Partnership expansion with Boehringer for oral delivery (May 2025) |
| Innovent Biologics | China | Niche Player | IBI362 (Phase III) | Asia Pacific | NMPA approval application for oral formulation (Sep 2025) |
| Terns Pharmaceuticals | US | Niche Player | TERN-601 (Phase II) | North America | Phase II initiation for NASH-obesity combination (Jul 2025) |
By Drug Class
GLP-1 receptor agonist monotherapy dominates the oral GLP-1 market by drug class at 78.4% share valued at USD 4.86 Billion in 2025. Oral semaglutide (Rybelsus) represents the sole approved product in this segment, achieving blockbuster status with over 8 million patients treated cumulatively since launch. The GLP-1 monotherapy mechanism provides 1.0-1.4% HbA1c reduction and 3-5 kg weight loss through appetite suppression and delayed gastric emptying. Once-daily dosing with fasting requirements (30 minutes before first meal) represents a compliance consideration, though patient acceptance exceeds 82% in real-world adherence studies. Eli Lilly's orforglipron targets this segment with small molecule chemistry offering potential advantages in bioavailability (85% versus 1% for peptide formulations) and manufacturing scalability.
Dual GLP-1/GIP receptor agonists represent 16.8% market share at USD 1.04 Billion in 2025, primarily through pipeline valuation as oral formulations approach commercialization. Tirzepatide (Mounjaro/Zepbound) has demonstrated superior efficacy to GLP-1 monotherapy in injectable form, with oral formulations in Phase III development. The dual mechanism provides 2.0-2.4% HbA1c reduction and 15-22% body weight loss through combined incretin pathway activation. Eli Lilly's oral tirzepatide program represents the most advanced dual agonist with potential 2027 approval. Multiple pharmaceutical companies are developing oral GLP-1/GIP candidates to capture the efficacy premium demonstrated by tirzepatide. Triple agonists (GLP-1/GIP/glucagon) in oral formulation account for 4.8% market share through pipeline valuation, with retatrutide and similar molecules advancing toward oral delivery.
By Therapeutic Indication
Type 2 diabetes leads therapeutic indications for the oral GLP-1 market at 82.6% share valued at USD 5.12 Billion in 2025. FDA approval of oral semaglutide for glycemic control in adults with type 2 diabetes established the commercial foundation. The American Diabetes Association and European Association for the Study of Diabetes guidelines recommend GLP-1 agonists as first-line therapy after metformin failure, with oral formulations increasingly preferred by patients over injectable alternatives. Approximately 537 million adults globally have diabetes, with over 90% classified as type 2. The oral GLP-1 penetration rate among treated type 2 diabetes patients reached 4.2% in the United States in 2025, indicating substantial headroom for growth. Prescribing has expanded beyond endocrinology into primary care settings, with 58% of new oral semaglutide prescriptions originating from non-specialist physicians.
Obesity and weight management represent 14.2% market share at USD 0.88 Billion in 2025, growing at 42.4% CAGR through 2034 as the fastest-expanding indication. FDA approval of higher-dose oral semaglutide for chronic weight management addresses the substantial unmet need among 650 million adults globally with obesity. Clinical trials demonstrate 15-17% body weight reduction with oral semaglutide at 50 mg daily doses, approaching injectable semaglutide (Wegovy) efficacy. Payer coverage for weight management has expanded significantly, with 68% of commercial health plans in the United States providing some obesity medication benefit in 2025 versus 42% in 2022. The obesity indication drives market expansion as patient populations exceed diabetes and willingness-to-pay remains high for effective weight loss. Cardiovascular risk reduction and other emerging indications account for the remaining 3.2% share.
By Formulation Type
Peptide-based oral formulations dominate the oral GLP-1 market at 94.2% share valued at USD 5.84 Billion in 2025. Novo Nordisk's SNAC absorption enhancer technology enables semaglutide peptide delivery through gastric epithelium, achieving approximately 1% bioavailability sufficient for therapeutic effect. The technology requires fasting administration and specific dosing protocols to ensure consistent absorption. Manufacturing complexity for peptide oral formulations requires specialized capabilities, limiting production scalability compared to traditional small molecule pharmaceuticals. Novo Nordisk has invested over USD 6 Billion in manufacturing capacity expansion since 2022 to address chronic supply shortages. The peptide formulation segment benefits from established clinical data and regulatory approval pathways.
Small molecule oral GLP-1 agonists represent 5.8% market share at USD 0.36 Billion in 2025, primarily through late-stage pipeline valuation. Non-peptide oral GLP-1 agonists including orforglipron (Eli Lilly), danuglipron (Pfizer), and LY3502970 (Eli Lilly) achieve 70-85% bioavailability without absorption enhancers. The small molecule approach eliminates fasting requirements, enables standard manufacturing processes, and potentially reduces production costs by 60-75% versus peptide formulations. Eli Lilly's orforglipron has demonstrated 7.9-14.7% body weight reduction in Phase III trials, approaching peptide GLP-1 efficacy. Small molecule formulations may enable once-weekly or less frequent oral dosing through extended half-life optimization. The segment is projected to capture 35% market share by 2034 as multiple approvals reshape competitive dynamics.
By Distribution Channel
Retail pharmacies lead the oral GLP-1 market by distribution channel at 62.4% share valued at USD 3.87 Billion in 2025. The oral formulation advantage enables standard pharmacy dispensing without specialty distribution requirements typical of injectable GLP-1 products. CVS, Walgreens, and other major retail chains have expanded oral GLP-1 inventory allocation to meet growing demand. Mail-order pharmacy services have increased prescription volumes by 34% year-over-year as chronic therapy maintenance drives automatic refill programs. Retail distribution supports the expansion of oral GLP-1 prescribing into primary care settings where injectable therapy referral barriers previously limited GLP-1 adoption.
Specialty pharmacies account for 24.8% market share at USD 1.54 Billion in 2025, primarily serving patients with complex insurance authorization requirements or those transitioning from injectable therapies. Hub service models coordinate prior authorization, benefits investigation, and patient support programs essential for high-cost chronic therapies. Specialty pharmacy involvement correlates with higher persistence rates (84% at 12 months versus 72% for retail-only distribution). Hospital pharmacies represent 8.6% share at USD 0.53 Billion, serving inpatient glycemic management and transition-of-care protocols. Direct-to-patient and telehealth distribution models account for the remaining 4.2% share, growing rapidly through digital health platforms expanding GLP-1 access.
Regional Analysis
North America Oral GLP-1 Market
North America commands 54.2% of the global oral GLP-1 market, valued at USD 3.36 Billion in 2025. The United States represents 94% of regional revenue at USD 3.16 Billion, driven by the highest obesity prevalence among developed nations (42% adult rate), favorable commercial insurance coverage, and established GLP-1 prescribing patterns developed through injectable products. Rybelsus achieved blockbuster status in the US market within 18 months of launch, faster than any previous diabetes therapy. Medicare Part D coverage expansion for obesity medications under consideration could add an estimated USD 2.4 Billion in annual market opportunity.
FDA regulatory pathways support rapid oral GLP-1 development with multiple expedited designations granted to pipeline candidates. The agency's willingness to accept weight loss as a primary endpoint has accelerated obesity indication approvals. Novo Nordisk's Durham, North Carolina manufacturing facility expansion will add 1.2 million square feet of oral semaglutide production capacity by 2027. Telehealth prescribing has emerged as a significant growth driver, with platforms like Ro, Calibrate, and WeightWatchers facilitating GLP-1 access for weight management. Canada contributes USD 200 million in 2025 market value with Health Canada approval aligning with FDA timelines. The Inflation Reduction Act's potential inclusion of oral GLP-1 products in Medicare drug price negotiation (beginning 2027) represents a regulatory consideration, though current demand substantially exceeds supply capacity.
Europe Oral GLP-1 Market
Europe accounts for 26.4% market share valued at USD 1.64 Billion in 2025 for the oral GLP-1 market. Germany leads regional adoption at USD 445 million (27.1% of Europe), driven by SHI coverage decisions and Novo Nordisk's commercial presence as a Copenhagen-headquartered company with strong European market access capabilities. The UK market at USD 365 million benefits from NHS England's Type 2 Diabetes Prevention Programme incorporating GLP-1 agonists. France at USD 295 million maintains centralized HTA evaluation through Haute Autorite de Sante with favorable ASMR ratings for oral semaglutide.
European Medicines Agency (EMA) centralized marketing authorization provides single approval across 27 EU member states plus EEA countries. The EMA approved oral semaglutide (Rybelsus) in 2020, approximately six months after FDA approval. Obesity prevalence in Europe reaches 23% of adults, lower than North America but representing substantial unmet need. Italy and Spain collectively represent USD 380 million in 2025 market value with national pricing negotiations following EMA approval. Novo Nordisk's Kalundborg, Denmark manufacturing complex serves as the primary oral semaglutide production site for European markets. The European obesity treatment landscape is evolving as multiple countries consider expanding coverage for weight management therapies beyond diabetes indications.
Asia Pacific Oral GLP-1 Market
Asia Pacific represents 14.2% market share valued at USD 0.88 Billion in 2025, positioned as the fastest-growing region at 28.6% CAGR through 2034 for the oral GLP-1 market. Japan contributes USD 385 million (43.8% of regional revenue) with PMDA approval and strong Novo Nordisk commercial presence established through decades of insulin market leadership. Japanese diabetes prevalence reaches 13.5% of adults, with cultural preference for oral medications supporting rapid Rybelsus adoption. Japanese pharmaceutical pricing and reimbursement frameworks provide favorable economics for oral GLP-1 therapies.
China's oral GLP-1 market reaches USD 285 million in 2025 with 35.4% growth projected annually through 2034. NMPA has approved oral semaglutide, addressing the world's largest diabetes population (140 million adults). Domestic pharmaceutical companies including Innovent Biologics and Hansoh Pharma are advancing oral GLP-1 candidates to compete with international products. India at USD 125 million represents substantial growth potential given 77 million diabetes patients, though affordability constraints limit premium oral GLP-1 penetration. South Korea contributes USD 65 million with advanced healthcare infrastructure supporting specialty pharmaceutical adoption. Australia rounds out regional activity with USD 35 million in market value. Manufacturing expansion in Asia Pacific, particularly CDMO capacity in China and India, may alleviate global supply constraints by 2028.
Latin America Oral GLP-1 Market
Latin America holds 3.4% market share valued at USD 0.21 Billion in 2025 for the oral GLP-1 market. Brazil dominates regional activity at USD 115 million (54.8% of Latin America), serving as Novo Nordisk's primary market entry point for specialty pharmaceutical products in the region. ANVISA regulatory pathways incorporate expedited review for diabetes therapies, with Rybelsus approval following FDA and EMA reference. Brazilian diabetes prevalence reaches 15.7% of adults, with a growing middle class expanding access to branded medications.
Mexico contributes USD 58 million with proximity to US pharmaceutical supply chains facilitating product access. COFEPRIS regulatory alignment with FDA procedures enables technology transfer. Argentina at USD 24 million maintains limited oral GLP-1 access concentrated in Buenos Aires metropolitan area due to currency challenges affecting import economics. Colombia and Chile collectively represent the remainder of regional activity with emerging specialty pharmaceutical capabilities. Regional growth at 22.4% CAGR through 2034 reflects expanding middle-class healthcare access and diabetes prevalence increases driven by urbanization and dietary shifts.
Middle East & Africa Oral GLP-1 Market
Middle East & Africa accounts for 1.8% market share valued at USD 0.11 Billion in 2025 for the oral GLP-1 market. The United Arab Emirates leads regional adoption at USD 38 million, driven by extremely high diabetes prevalence (16.3% of adults) and advanced healthcare infrastructure in Dubai and Abu Dhabi. UAE healthcare free zones have facilitated early Rybelsus access for Emirati citizens. Saudi Arabia contributes USD 35 million with Vision 2030 healthcare investments prioritizing diabetes management. Saudi diabetes prevalence reaches 18.3% of adults, among the highest globally.
Israel at USD 22 million benefits from advanced biotechnology infrastructure and regulatory alignment with European systems. South Africa represents the primary sub-Saharan market at USD 10 million, with specialty pharmaceutical distribution limited to major metropolitan centers. High diabetes prevalence across the Gulf Cooperation Council countries (14-20% of adults) creates substantial demand, though affordability constraints limit penetration in lower-income MEA markets. Regional growth at 24.2% CAGR through 2034 reflects healthcare modernization investments and increasing diabetes prevalence driven by lifestyle factors.
Oral GLP-1 Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
23.8%
The Forecast Market
Size for 2034 in USD:
$USD 42.50 B
Get more details on this report -
Market Key Segments
By Drug Class
- GLP-1 Receptor Agonist Monotherapy
- Dual GLP-1/GIP Receptor Agonists
- Triple Agonists (GLP-1/GIP/Glucagon)
By Therapeutic Indication
- Type 2 Diabetes
- Obesity and Weight Management
- Cardiovascular Risk Reduction
- Other Indications
By Formulation Type
- Peptide-Based Oral Formulations
- Small Molecule Oral GLP-1 Agonists
By Distribution Channel
- Retail Pharmacies
- Specialty Pharmacies
- Hospital Pharmacies
- Direct-to-Patient and Telehealth
Regional Analysis and Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 6.20 B |
| Forecast Revenue (2034) | USD 42.50 B |
| CAGR (2025-2034) | 23.8% |
| Historical data | 2021-2024 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Drug Class, (GLP-1 Receptor Agonist Monotherapy, Dual GLP-1/GIP Receptor Agonists, Triple Agonists (GLP-1/GIP/Glucagon)), By Therapeutic Indication, (Type 2 Diabetes, Obesity and Weight Management, Cardiovascular Risk Reduction, Other Indications), By Formulation Type, (Peptide-Based Oral Formulations, Small Molecule Oral GLP-1 Agonists), By Distribution Channel, (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies, Direct-to-Patient and Telehealth) |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | NOVO NORDISK, ELI LILLY, PFIZER, AMGEN, ASTRAZENECA, SANOFI, BOEHRINGER INGELHEIM, MERCK & CO., ROCHE, ZEALAND PHARMA, INNOVENT BIOLOGICS, HANSOH PHARMA, STRUCTURE THERAPEUTICS, VIKING THERAPEUTICS, TERNS PHARMACEUTICALS, Others |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Oral GLP-1 Market?
Global Oral GLP-1 market valued at USD 5.01B in 2024, reaching USD 42.5B by 2034, growing at a CAGR of 23.8% from 2026–2034.
Who are the major players in the Oral GLP-1 Market?
NOVO NORDISK, ELI LILLY, PFIZER, AMGEN, ASTRAZENECA, SANOFI, BOEHRINGER INGELHEIM, MERCK & CO., ROCHE, ZEALAND PHARMA, INNOVENT BIOLOGICS, HANSOH PHARMA, STRUCTURE THERAPEUTICS, VIKING THERAPEUTICS, TERNS PHARMACEUTICALS, Others
Which segments covered the Oral GLP-1 Market?
By Drug Class, (GLP-1 Receptor Agonist Monotherapy, Dual GLP-1/GIP Receptor Agonists, Triple Agonists (GLP-1/GIP/Glucagon)), By Therapeutic Indication, (Type 2 Diabetes, Obesity and Weight Management, Cardiovascular Risk Reduction, Other Indications), By Formulation Type, (Peptide-Based Oral Formulations, Small Molecule Oral GLP-1 Agonists), By Distribution Channel, (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies, Direct-to-Patient and Telehealth)
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date
